clinical trial · NCT07357415
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Eli Lilly and Company·phase3·recruiting·n = 600
ObesityOverweightRetatrutide
brief summary
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
started
Jan 24, 2026
primary completion
Oct 1, 2028
completion
Nov 1, 2028
last updated
Apr 20, 2026
official title
A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol